Previous close | 17.80 |
Open | 17.50 |
Bid | 17.40 x N/A |
Ask | 17.70 x N/A |
Day's range | 17.50 - 17.50 |
52-week range | 13.20 - 21.90 |
Volume | |
Avg. volume | 49 |
Market cap | 2.372B |
Beta (5Y monthly) | 0.02 |
PE ratio (TTM) | 1,750.00 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 16 June 2016 |
1y target est | N/A |
Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose. The study, "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", was published in the Journal of Clinical Pharmacology (Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers:
Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.